Clinical trials

Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.